Publications by authors named "Meis Omran"

Claim this Profile
T
TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype.
Alexander Sun Zhang, Meis Omran, Cecilia Arthur, Helena Malmgren, Rita Barbosa-Matos

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The argument for screening programs in previvors with Li-Fraumeni syndrome.
Meis Omran, David Malkin

Expert Rev Anticancer Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant-is it too soon to draw conclusions?
Meis Omran, David Malkin

J Natl Cancer Inst· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of heritable TP53-related cancer syndrome in Sweden-a nationwide study of genotype-phenotype correlations in 90 families.
Meis Omran, Yaxuan Liu, Alexander Sun Zhang, Anna Poluha, Marie Stenmark-Askmalm

Eur J Hum Genet· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Meis Omran, Hemming Johansson, Claudia Lundgren, Gustav Silander, Marie Stenmark-Askmalm

Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary -Related Cancer Syndrome Study (SWEP53).
Meis Omran, Emma Tham, Yvonne Brandberg, Håkan Ahlström, Claudia Lundgren

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body MRI within a surveillance program for carriers with clinically actionable germline variants - the Swedish constitutional study SWEP53.
Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner

Hered Cancer Clin Pract· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Pharmacologic symptom relief at the end of life].
Meis Omran, Staffan Lundström

Lakartidningen· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis